Micronoma in the News

When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...

The revelation that our commensal bacteria play important roles in health and disease has turned the microbiome into one of the most active frontiers of biomedicine. Yet our efforts to turn our “inner bugs” into drugs have long been limited to investigational fecal...

As a postdoc at the Broad Institute of MIT and Harvard in 2008, cancer biologist Ravid Straussman worked on a collaborative effort to screen normal cells for their influence on cancer cells’ responses to various anticancer therapies. The project turned up hundreds of...

NEW YORK – Microbial cancer detection firm Micronoma said Tuesday that it is collaborating with... Read Article

After controlling for high levels of bacterial contamination in their lab and reagents, researchers detect microbial genetic material in plasma samples from healthy people and cancer patients. Read the full article in The Scientist

Micronoma, a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round. Read full story.

Read the full article on GenomeWeb.

San Diego-based Micronoma, a startup using microbiome analysis for early cancer detection, has appointed Magda Marquet as chairman of the firm’s board.

Microbiomics is taking a sharp turn. Until now, the field was limited to fecal transplants from healthy patients to those with gut conditions. The transplant is an awkward procedure that also creates regulatory and other challenges. Read More.

  NEW YORK – Following a successful $3 million seed funding round earlier this month, University of California, San Diego spinout Micronoma is commercializing a blood-based diagnostic assay that identifies a patient's organ microbiome signature to potentially...

Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. Read More.

San Diego-based Micronoma closed $3 million in seed financing to support the development of its microbiome-based cancer detection technology. Full Article

San Diego-based Micronoma, a startup working on early cancer detection, announced this morning that it has raised $3M in a seed financing round. The funding was led by SymBiosis, LLc. According to the company, Read Article

  A study suggests the potential for a noninvasive diagnostic that could detect tumors early and differentiate between disease types. Read More.

The story behind this paper begins with the loss of my grandmother to pancreatic cancer and the relentless pursuit to understand her disease. Projects along my educational path seemed like diversions (e.g. infectious disease genomics) but provided valuable skills to...